166 related articles for article (PubMed ID: 35785200)
1. Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas.
Takei J; Fukasawa N; Tanaka T; Yamamoto Y; Tamura R; Sasaki H; Akasaki Y; Kamata Y; Murahashi M; Shimoda M; Murayama Y
Front Oncol; 2022; 12():898614. PubMed ID: 35785200
[TBL] [Abstract][Full Text] [Related]
2.
Suzuki T; Takei J; Fukasawa N; Suzuki K; Ogawa D; Yamamoto Y; Akasaki Y; Murayama Y; Shimoda M; Miyake K; Tanaka T
World Neurosurg; 2023 Jul; 175():e1364-e1374. PubMed ID: 37187346
[TBL] [Abstract][Full Text] [Related]
3. "Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.
Yamamoto Y; Tamura R; Tanaka T; Ohara K; Tokuda Y; Miyake K; Takei J; Akasaki Y; Yoshida K; Murayama Y; Sasaki H
Oncotarget; 2017 Nov; 8(61):103890-103899. PubMed ID: 29262608
[TBL] [Abstract][Full Text] [Related]
4. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.
Tamura R; Tanaka T; Ohara K; Miyake K; Morimoto Y; Yamamoto Y; Kanai R; Akasaki Y; Murayama Y; Tamiya T; Yoshida K; Sasaki H
Cancer Sci; 2019 Feb; 110(2):499-508. PubMed ID: 30467920
[TBL] [Abstract][Full Text] [Related]
5. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.
Nowosielski M; Wiestler B; Goebel G; Hutterer M; Schlemmer HP; Stockhammer G; Wick W; Bendszus M; Radbruch A
Neurology; 2014 May; 82(19):1684-92. PubMed ID: 24727314
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
7. FAT1 modulates EMT and stemness genes expression in hypoxic glioblastoma.
Srivastava C; Irshad K; Dikshit B; Chattopadhyay P; Sarkar C; Gupta DK; Sinha S; Chosdol K
Int J Cancer; 2018 Feb; 142(4):805-812. PubMed ID: 28994107
[TBL] [Abstract][Full Text] [Related]
8. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
10. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
11. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment.
Ezaki T; Tanaka T; Tamura R; Ohara K; Yamamoto Y; Takei J; Morimoto Y; Imai R; Kuranai Y; Akasaki Y; Toda M; Murayama Y; Miyake K; Sasaki H
Brain Tumor Pathol; 2024 Apr; 41(2):61-72. PubMed ID: 38619734
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Schaub C; Kebir S; Junold N; Hattingen E; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Niessen M; Mack F; Stuplich M; Tzaridis T; Bähr O; Kortmann RD; Schlegel U; Schmidt-Graf F; Rohde V; Braun C; Hänel M; Sabel M; Gerlach R; Krex D; Belka C; Vatter H; Proescholdt M; Herrlinger U; Glas M
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1581-1589. PubMed ID: 29808316
[TBL] [Abstract][Full Text] [Related]
13. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Nowosielski M; Ellingson BM; Chinot OL; Garcia J; Revil C; Radbruch A; Nishikawa R; Mason WP; Henriksson R; Saran F; Kickingereder P; Platten M; Sandmann T; Abrey LE; Cloughesy TF; Bendszus M; Wick W
Neuro Oncol; 2018 Mar; 20(4):557-566. PubMed ID: 29016943
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Said HM; Hagemann C; Carta F; Katzer A; Polat B; Staab A; Scozzafava A; Anacker J; Vince GH; Flentje M; Supuran CT
Bioorg Med Chem; 2013 Jul; 21(13):3949-57. PubMed ID: 23706268
[TBL] [Abstract][Full Text] [Related]
15. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
16. Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.
Nigim F; Cavanaugh J; Patel AP; Curry WT; Esaki S; Kasper EM; Chi AS; Louis DN; Martuza RL; Rabkin SD; Wakimoto H
J Neuropathol Exp Neurol; 2015 Jul; 74(7):710-22. PubMed ID: 26083570
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab.
Tamura R; Tanaka T; Morimoto Y; Kuranari Y; Yamamoto Y; Takei J; Murayama Y; Yoshida K; Sasaki H
Ann Transl Med; 2020 Mar; 8(6):297. PubMed ID: 32355741
[TBL] [Abstract][Full Text] [Related]
18. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
19. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
Swanson KR; Chakraborty G; Wang CH; Rockne R; Harpold HL; Muzi M; Adamsen TC; Krohn KA; Spence AM
J Nucl Med; 2009 Jan; 50(1):36-44. PubMed ID: 19091885
[TBL] [Abstract][Full Text] [Related]
20. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Said HM; Hagemann C; Staab A; Stojic J; Kühnel S; Vince GH; Flentje M; Roosen K; Vordermark D
Radiother Oncol; 2007 Jun; 83(3):398-405. PubMed ID: 17524506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
